A method of inhibiting skin cancer by administering to a subject in need thereof a double stranded RNA interference (RNAi) agent comprising at least one of (i) a first double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a CD320 gene wherein the first dsRNA comprises a sense strand and an antisense strand forming a duplex, and (ii) a second dsRNA for inhibiting the expression of a LRP2 gene wherein the second dsRNA comprises a sense strand and an antisense strand forming a duplex, wherein the sense strand of the first dsRNA is at least substantially complementary to the antisense strand of the first dsRNA and the sense strand of the second dsRNA is at least substantially complementary to the antisense strand of the second dsRNA and the use of the RNAi agent as a pharmaceutical composition for the treatment of cancer in subjects in need of treatment.
A system and method for analyzing a sputum sample from a subject suspected of having lung cancer comprising obtaining a plurality of cells from the sputum sample from the subject, marking the plurality of cells with i) a plurality of cell lineage specific marker compositions, ii) a cell viability composition and iii) a tetra (4-carboxyphenyl) porphyrin (TCPP) composition; analyzing with the flow cytometer the plurality of cells marked with i-iii to obtain a subpopulation selected for cell size from the plurality of cells based upon an automatically selected bead size exclusion gate; from the cell size selected subpopulation, selecting a viable singlet population of cells using an automated non-debris gate and an automated singlets gate; from the viable singlet population of cells, obtaining flow cytometer values based upon the plurality of cell lineage specific marker compositions, the viability marker and the TCPP marker; applying a trained classifier to meta data from the subject and the flow cytometric values obtained; and generating, based upon the application of the trained classifier, a classification for the sputum sample wherein the classification is selected from a plurality of classification options comprising cancer and non-cancer.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
4.
Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning
A system and method for analyzing a sputum sample from a subject suspected of having lung cancer comprising obtaining a plurality of cells from the sputum sample from the subject, marking the plurality of cells with i) a plurality of cell lineage specific marker compositions, ii) a cell viability composition and iii) a tetra (4-carboxyphenyl) porphyrin (TCPP) composition; analyzing with the flow cytometer the plurality of cells marked with i-iii to obtain a subpopulation selected for cell size from the plurality of cells based upon an automatically selected bead size exclusion gate; from the cell size selected subpopulation, selecting a viable singlet population of cells using an automated non-debris gate and an automated singlets gate; from the viable singlet population of cells, obtaining flow cytometer values based upon the plurality of cell lineage specific marker compositions, the viability marker and the TCPP marker; applying a trained classifier to meta data from the subject and the flow cytometric values obtained; and generating, based upon the application of the trained classifier, a classification for the sputum sample wherein the classification is selected from a plurality of classification options comprising cancer and non-cancer.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
5.
COMPOSITIONS AND METHODS FOR USE IN FLOW CYTOMETRY
A compensation bead comprising an amine functionalized bead modified covalently or non-covalently with a carboxyaryl porphyrin, a method for making the amine functionalized bead with the carboxyaryl porphyrin and a method of using the amine functionalized bead with the carboxyaryl porphyrin as a marker for the carboxyaryl porphyrin labeled cells and particles.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of lung health and cancer screening
7.
DETECTION OF EARLY-STAGE LUNG CANCER IN SPUTUM USING AUTOMATED FLOW CYTOMETRY AND MACHINE LEARNING
iiiiiiiiiiiii to obtain a subpopulation selected for cell size from the plurality of cells based upon an automatically selected bead size exclusion gate; from the cell size selected subpopulation, selecting a viable singlet population of cells using an automated non-debris gate and an automated singlets gate; from the viable singlet population of cells, obtaining flow cytometer values based upon the plurality of cell lineage specific marker compositions, the viability marker and the TCPP marker; applying a trained classifier to meta data from the subject and the flow cytometric values obtained; and generating, based upon the application of the trained classifier, a classification for the sputum sample wherein the classification is selected from a plurality of classification options comprising cancer and non-cancer.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of lung health and cancer screening
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing information to patients in the field of medical diagnostic screening; providing medical information; providing medical diagnostic services, namely, medical analysis services for screening and diagnostic purposes provided by medical laboratories and medical diagnostic testing; providing information in the field of lung health and cancer screening
11.
DETECTION OF EARLY-STAGE LUNG CANCER IN SPUTUM USING AUTOMATED FLOW CYTOMETRY AND MACHINE LEARNING
A system and method for analyzing a sputum sample from a subject suspected of having lung cancer comprising obtaining a plurality of cells from the sputum sample from the subject, marking the plurality of cells with i) a plurality of cell lineage specific marker compositions, ii) a cell viability composition and iii) a tetra (4-carboxyphenyl) porphyrin (TCPP) composition; analyzing the plurality of cells marked with iiii to obtain a subpopulation selected for cell size, selecting a viable singlet population of cells and obtaining flow cytometer values based upon the plurality of cell lineage specific marker compositions, the viability marker and the TCPP marker; applying a trained classifier to meta data from the subject and the flow cytometric values obtained; and generating, based upon the application of the trained classifier, a classification for the sputum sample wherein the classification is selected from a plurality of classification options comprising cancer and non-cancer.
A system and method for analyzing a sputum sample from a subject suspected of having lung cancer comprising obtaining a plurality of cells from the sputum sample from the subject, marking the plurality of cells with i) a plurality of cell lineage specific marker compositions, ii) a cell viability composition and iii) a tetra (4-carboxyphenyl) porphyrin (TCPP) composition; analyzing the plurality of cells marked with iiii to obtain a subpopulation selected for cell size, selecting a viable singlet population of cells and obtaining flow cytometer values based upon the plurality of cell lineage specific marker compositions, the viability marker and the TCPP marker; applying a trained classifier to meta data from the subject and the flow cytometric values obtained; and generating, based upon the application of the trained classifier, a classification for the sputum sample wherein the classification is selected from a plurality of classification options comprising cancer and non-cancer.
A compound comprising an amine functionalized bead modified covalently or non-covalently with TCPP, a method for making the amine functionalized bead with TCPP and a method of using the amine functionalized bead with TCPP as a marker for TCPP labeled cells and particles.
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
C09B 47/06 - Preparation from carboxylic acids or derivatives thereof
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
A double stranded RNA interference (RNAi) agent comprising at least one of (i) a first double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a CD320 gene wherein the first dsRNA comprises a sense strand and an antisense strand forming a duplex, (ii) a second dsRNA for inhibiting the expression of a LRP2 gene wherein the second dsRNA comprises a sense strand and an antisense strand forming a duplex, or (iii) a cocktail of (i) and (ii) and wherein the sense strand of the first dsRNA is at least substantially complementary to the antisense strand of the first dsRNA and the sense strand of the second dsRNA is at least substantially complementary to the antisense strand of the second dsRNA and the use of the RNAi agent as a pharmaceutical composition for the treatment of cancer in subjects in need of treatment.
iiiiiiiiiii) and wherein the sense strand of the first dsRNA is at least substantially complementary to the antisense strand of the first dsRNA and the sense strand of the second dsRNA is at least substantially complementary to the antisense strand of the second dsRNA and the use of the RNAi agent as a pharmaceutical composition for the treatment of cancer in subjects in need of treatment.
One embodiment of the present invention provides for a cobalamin complex or the pharmaceutically acceptable salt, stereoisomers, solvate or polymorph thereof comprising a siRNA sequence that is complementary to a nucleic acid sequence that codes for a target protein within a cell wherein the siRNA sequence is bound to a cobalamin and wherein the cobalamin is complexed with a cobalamin binding protein, a pharmaceutical composition formed with the complex and a method of using the complex to treat a disease associated with the target protein.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A compound, pharmaceutical composition made therefrom and a method of treating proliferative disease in a subject in need thereof wherein the compound comprises an engineered soluble receptor or a pharmaceutically acceptable salt, stereoisomers, solvate or polymorph thereof with a binding affinity for TCN2/Cbl in a plasma of subject to which the compound is administered wherein the binding affinity for TCN2/Cbl in the plasma is higher than as compared to endogenous sCD320 for TCN2/Cbl under the same conditions.
Predicting the likelihood of lung disease in a subject, comprising labeling an ex-vivo sputum sample from a subject with one or more of the following: a first labeled probe that binds a biomarker expressed on a white blood cell population in the sample; a second labeled probe selected from the group consisting of: a granulocyte probe, a T-cell probe, a B-cell probe, or any combination thereof; a third labeled probe that binds a biomarker on a macrophage cell population; a fourth labeled probe that binds to a disease related cell in the sample; a fifth labeled probe that binds to a biomarker expressed on an epithelial cell population; and a sixth labeled probe that binds to a cell surface biomarker expressed on an epithelial cell population to obtain data comprising a mean fluorescent signature and detecting a profile based upon a presence or absence of labeled probes.
iiiiiiiiiii) and wherein the sense strand of the first dsRNA is at least substantially complementary to the antisense strand of the first dsRNA and the sense strand of the second dsRNA is at least substantially complementary to the antisense strand of the second dsRNA and the use of the RNAi agent as a pharmaceutical composition for the treatment of cancer in subjects in need of treatment.
A double stranded RNA interference (RNAi) agent comprising at least one of (i) a first double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a CD320 gene wherein the first dsRNA comprises a sense strand and an antisense strand forming a duplex, (ii) a second dsRNA for inhibiting the expression of a LRP2 gene wherein the second dsRNA comprises a sense strand and an antisense strand forming a duplex, or (iii) a cocktail of (i) and (ii) and wherein the sense strand of the first dsRNA is at least substantially complementary to the antisense strand of the first dsRNA and the sense strand of the second dsRNA is at least substantially complementary to the antisense strand of the second dsRNA and the use of the RNAi agent as a pharmaceutical composition for the treatment of cancer in subjects in need of treatment.
Predicting the likelihood of lung disease in a subject, comprising labeling an ex-vivo sputum sample from a subject with one or more of the following: a first labeled probe that binds a biomarker expressed on a white blood cell population in the sample; a second labeled probe selected from the group consisting of: a granulocyte probe, a T-cell probe, a B-cell probe, or any combination thereof; a third labeled probe that binds a biomarker on a macrophage cell population; a fourth labeled probe that binds to a disease related cell in the sample; a fifth labeled probe that binds to a biomarker expressed on an epithelial cell population; and a sixth labeled probe that binds to a cell surface biomarker expressed on an epithelial cell population to obtain data comprising a mean fluorescent signature and detecting a profile based upon a presence or absence of labeled probes.
Predicting the likelihood of lung disease in a subject, comprising labeling an ex-vivo sputum sample from a subject with one or more of the following: a first labeled probe that binds a biomarker expressed on a white blood cell population in the sample; a second labeled probe selected from the group consisting of: a granulocyte probe, a T-cell probe, a B-cell probe, or any combination thereof; a third labeled probe that binds a biomarker on a macrophage cell population; a fourth labeled probe that binds to a disease related cell in the sample; a fifth labeled probe that binds to a biomarker expressed on an epithelial cell population; and a sixth labeled probe that binds to a cell surface biomarker expressed on an epithelial cell population to obtain data comprising a mean fluorescent signature and detecting a profile based upon a presence or absence of labeled probes.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Cancer screening test kit comprised of implements and
container for collecting patient samples for analysis. Medical testing for diagnostic purposes or treatment
purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical agents and preparations for medical and clinical
laboratory diagnostic use; assay kits containing chemical
agents and preparations for medical and clinical laboratory
diagnostic use; cancer screening test kit comprised of
implements and container for collecting patient samples for
analysis; medical testing for diagnostic purposes or
treatment purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical agents and preparations for scientific purposes
other than for medical or veterinary use; assay kits
containing chemical agents and preparations for scientific
purposes other than for medical or veterinary use.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical agents and preparations for scientific purposes other than for medical or veterinary use; assay kits containing chemical agents and preparations for scientific purposes other than for medical or veterinary use
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
[ Chemical agents and preparations for scientific purposes other than for medical or veterinary use; ] assay kits containing chemical agents and preparations for scientific purposes other than for medical or veterinary use
One embodiment of the present invention provides for a method of determining if a sputum sample contains dysplastic or carcinomic cells by obtaining a sputum sample containing cells. The sputum sample is labeled with TCPP to stain cells suspected to be dysplastic or carcinomic. The labeled sputum sample is excited with an excitation wavelength of light of about 475 nm +/- 30 nm and emission at about 560 nm +/- 30nm is detected from cells identified to be macrophages. An imager focuses on the plasma membrane of one or more cells suspected to be dysplastic or carcinomic and emission at about 655 nm +/- 30 nm, if present, is detected for TCPP labeled cells of the sputum sample after focusing on the plasma membrane of the cells of the sputum sample. Photon flux for each pixel of a sensor is measured to obtain a value for the imaged cell. The measured value is scored to determine if a cell is cancerous or dysplastic.
One embodiment of the present invention provides for a method of determining if a sputum sample contains dysplastic or carcinomic cells by obtaining a sputum sample containing cells. The sputum sample is labeled with TCPP to stain cells suspected to be dysplastic or carcinomic. The labeled sputum sample is excited with an excitation wavelength of light of about 475 nm+/−30 nm and emission at about 560 nm+/−30 nm is detected from cells identified to be macrophages. An imager focuses on the plasma membrane of one or more cells suspected to be dysplastic or carcinomic and emission at about 655 nm+/−30 nm, if present, is detected for TCPP labeled cells of the sputum sample after focusing on the plasma membrane of the cells of the sputum sample. Photon flux for each pixel of a sensor is measured to obtain a value for the imaged cell. The measured value is scored to determine if a cell is cancerous or dysplastic.
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical agents and preparations for medical and clinical
laboratory diagnostic use; assay kits containing chemical
agents and preparations for medical and clinical laboratory
diagnostic use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical agents and preparations for medical and clinical laboratory diagnostic use; Assay kits containing chemical agents and preparations for medical and clinical laboratory diagnostic use
